Baseline variables predictive of conversion from possible to clinically definite MS: ETOMS results

被引：0
|
作者：
Martinelli-Boneschi, F
Hartung, HP
Sorensen, PS
Edan, G
Fernandez, O
Durelli, L
Roveris, M
Seeldrayers, P
Barkhof, F
Filippi, M
Hommes, O
Comi, G
机构：
来源：
NEUROLOGY | 2002年 / 58卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A504 / A504
页数：1
相关论文
共 50 条
  • [31] Depression and fatigue in patients with clinically definite multiple sclerosis: results from the Pacific Northwest Multiple Sclerosis Registry
    Lucassen, E.
    Cohan, S.
    Chen, C.
    Jin, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 626 - 627
  • [32] Multiple sclerosis quality of life inventory in patients at risk for clinically definite multiple sclerosis: results from the CHAMPIONS trial
    Miller, D. M.
    Kollman, C.
    Kinkel, R. P.
    MULTIPLE SCLEROSIS, 2006, 12 : S110 - S110
  • [33] Cladribine tablets in the ORACLE-MS study open-label maintenance period: Analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS)
    Comi, Giancarlo
    Leist, Thomas
    Freedman, Mark S.
    Cree, Bruce A. C.
    Coyle, Patricia K.
    Hartung, Hans-Peter
    Vermersch, Patrick
    Damian, Doris
    Dangond, Fernando
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP5 - NP5
  • [34] Efficacy of cladribine tablets in patients after conversion to clinically definite multiple sclerosis (CDMS): Analysis of the ORACLE-MS study open-label maintenance period
    Comi, G.
    Leist, T.
    Freedman, M. S.
    Cree, B. A. C.
    Coyle, P. K.
    Hartung, H-P.
    Vermersch, P.
    Damian, D.
    Dangond, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 193 - 194
  • [35] Cladribine tablets in the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS).
    Comi, G.
    Leist, T.
    Freedman, M. S.
    Cree, B. A. C.
    Coyle, P. K.
    Hartung, H. -P.
    Vermersch, P.
    Damian, D.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 15 - 16
  • [36] Cladribine tablets in the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS)
    Comi, Giancarlo
    Leist, Thomas
    Freedman, Mark
    Cree, Bruce
    Coyle, Patricia
    Hartung, Hans-Peter
    Vermersch, Patrick
    Damian, Doris
    Dangond, Fernando
    NEUROLOGY, 2017, 88
  • [37] Depression and Fatigue in Clinically Definite Multiple Sclerosis (CDMS, McDonald Criteria) - Results from the Oregon Multiple Sclerosis Registry (OMSR)
    Cohan, Stanley
    Chen, Chiayi
    Jin, Ruyun
    Bodie, Adam
    Stuchiner, Tamela
    Grunkemeier, Garry
    NEUROLOGY, 2010, 74 (09) : A362 - A362
  • [38] HETEROGENEITY IN REPORTED BASELINE DATA AND VARIABLES FROM OBSERVATIONAL STUDIES IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM A SYSTEMATIC REVIEW
    Wong, Charlotte
    van Oostrom, Joep M.
    Bossuyt, Peter
    Pittet, Valerie
    Hanzel, Jurij
    Samaan, Mark A.
    Tripathi, Monika
    Czuber-Dochan, Wladyslawa
    Burisch, Johan M.
    Leone, Salvatore
    Saldana, Roberto
    Baert, Filip J.
    Kopylov, Uri
    Jaghult, Susanna
    Adamina, Michel
    Gecse, Krisztina B.
    Arebi, Naila
    GASTROENTEROLOGY, 2022, 162 (07) : S1038 - S1039
  • [39] Treatment responses, disability outcomes and prognosis of a cohort of Sri Lankan patients with clinically definite multiple sclerosis: Preliminary data from a dedicated MS clinic
    Senanayake, B.
    Aravinthan, M.
    Rajapakshe, I.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [40] Relation of fatigue to clinical and patient-reported disease measures in MS - baseline results from the CombatMS Study
    Englund, S.
    Kierkegaard, M.
    Frisell, T.
    Piehl, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 193 - 193
12345